Xilio Therapeutics reported revenue of $18.69M and net income of -$6.37M for the quarter ended Jun 2026, up 131.2% year over year. This income statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||
| Revenue | 2.36M | 2.26M | 1.72M | 2.93M | 8.08M | 19.07M | 13.69M | 12.65M | 18.69M | |||||||||||||||
| Operating items | ||||||||||||||||||||||||
| Research & DevelopmentR&D | 10.47M | 11.35M | 14.92M | 16.25M | 13.04M | 15.00M | 16.13M | 13.22M | 11.05M | 11.74M | 10.40M | 11.22M | 10.76M | 8.84M | 8.27M | 15.33M | 14.32M | 18.12M | 19.83M | 14.56M | ||||
| Selling, General & AdministrativeSG&A | 5.49M | 8.20M | 6.30M | 8.31M | 7.17M | 8.17M | 7.39M | 6.90M | 6.31M | 6.39M | 6.14M | 5.82M | 6.31M | 6.52M | 8.52M | 7.12M | 6.67M | 7.40M | 6.93M | 7.62M | ||||
| Restructuring CostsRestructuring | 0.95M | 0.03M | -0.04M | |||||||||||||||||||||
| Operating ExpensesOpex | 15.96M | 19.56M | 21.22M | 24.55M | 20.21M | 23.17M | 23.53M | 20.12M | 17.36M | 18.13M | 17.49M | 17.06M | 17.02M | 15.35M | 16.78M | 22.45M | 21.00M | 25.52M | 26.76M | 22.18M | ||||
| Operating IncomeOp. Inc | -15.96M | -19.56M | -21.22M | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M | -17.36M | -18.13M | -17.49M | -14.70M | -14.76M | -13.63M | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M | -3.49M | ||||
| EBIT | -15.96M | -19.56M | -21.22M | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M | -17.36M | -18.13M | -17.49M | -14.70M | -14.76M | -13.63M | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M | -3.49M | ||||
| Non-operating items | ||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.29M | 0.17M | 0.13M | |||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.29M | -0.14M | -0.13M | -0.06M | 0.42M | 0.70M | 0.88M | 0.76M | 0.61M | 0.47M | 0.28M | 0.78M | 0.74M | 0.54M | 0.59M | -1.43M | 1.02M | 0.92M | 1.28M | 1.06M | ||||
| Non Operating IncomeNon Op. Inc. | -0.29M | -0.14M | -0.13M | -0.06M | 0.42M | 0.70M | 0.88M | 0.76M | 0.61M | 0.47M | 0.28M | 0.78M | 0.74M | 0.54M | 0.59M | -1.48M | -14.36M | 22.20M | 4.58M | -2.88M | ||||
| Net income details | ||||||||||||||||||||||||
| EBT | -16.25M | -19.73M | -21.35M | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M | -17.36M | -18.13M | -17.49M | -14.70M | -14.76M | -13.63M | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M | -3.49M | ||||
| Profit After TaxPAT | -16.25M | -19.70M | -21.35M | -24.61M | -19.79M | -22.42M | -22.65M | -19.36M | -16.75M | -17.66M | -17.20M | -13.93M | -14.02M | -13.09M | -13.27M | -15.84M | -16.29M | 10.36M | -9.53M | -6.37M | ||||
| Income from Continuing OperationsIncome (Continuing) | -16.25M | -19.73M | -21.35M | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M | -17.36M | -18.13M | -17.49M | -14.70M | -14.76M | -13.63M | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M | -3.49M | ||||
| Consolidated Net IncomeConsol Net Inc. | -16.25M | -19.73M | -21.35M | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M | -17.36M | -18.13M | -17.49M | -14.70M | -14.76M | -13.63M | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M | -3.49M | ||||
| Income towards Parent CompanyParent Net Inc | -16.25M | -19.73M | -21.35M | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M | -17.36M | -18.13M | -17.49M | -14.70M | -14.76M | -13.63M | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M | -3.49M | ||||
| Net Income towards Common StockholdersNet Income | -16.25M | -19.73M | -21.35M | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M | -17.36M | -18.13M | -17.49M | -14.70M | -14.76M | -13.63M | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M | -3.49M | ||||
| Additional items | ||||||||||||||||||||||||
| EPS (Basic) | -297.84 | -49.27 | -10.92 | -12.55 | -10.32 | -11.84 | -12.01 | -10.25 | -8.83 | -9.23 | -8.77 | -3.56 | -3.26 | -3.57 | -2.60 | -2.09 | -0.19 | -1.42 | -0.86 | -0.18 | ||||
| Shares Outstanding | 0.05M | 0.40M | 1.95M | 1.96M | 1.96M | 1.96M | 1.96M | 1.96M | 1.97M | 1.96M | 1.99M | 4.13M | 4.53M | 3.82M | 5.34M | 6.89M | 10.29M | 8.36M | 16.35M | 19.40M | ||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.05M | 0.40M | 1.96M | 1.96M | 1.96M | 1.96M | 1.96M | 1.97M | 1.97M | 1.97M | 1.99M | 4.13M | 4.53M | 3.27M | 5.34M | 6.89M | 10.29M | 8.36M | 16.35M | 19.40M | ||||
| EBITDA | -15.96M | -19.56M | -21.22M | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M | -17.36M | -18.13M | -17.49M | -14.70M | -14.76M | -13.63M | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M | -3.49M | ||||
| Interest ExpensesInt Expense | 0.29M | 0.17M | 0.13M |